Transcortin: A Corticosteroid-binding Protein of Plasma. VII. Half-Life in Normal and Estrogen-treated Subjects *

Abstract

I125-labeled transcortin has been injected intravenously into two estrogen-treated patients with carcinoma of the prostate and three normal subjects. The clearance from the plasma indicated a half-life of approximately five days in the subjects studied. No difference was demonstrated in the clearance of transcortin between the normal subjects and the estrogen-treated subjects. On the basis of the experiments presented, the elevated transcortin levels induced by estrogen are apparently due to increased synthesis of the protein.